



Urgent Review: Emerging Safety Signals Linking COVID-19 mRNA Vaccines to Reproductive Health Outcomes

December 2025

Dear Colleague,

Following our initial communication, NORTH Group writes to share significant new evidence raising urgent concerns about the safety of COVID-19 mRNA vaccines for reproductive health. A growing body of peer-reviewed research and epidemiological data points to safety signals that we believe warrant your professional attention and dialogue.

The core of our concern is the **application of the mRNA/lipid nanoparticle (LNP) platform to a healthy population, including those of reproductive age, without adequate long-term safety testing**. The precautionary principle was bypassed. We now face emerging trends that cannot be ignored:

- **A significant decline in birth rates** across Europe, beginning in early 2022, temporally aligned with mass vaccination campaigns to the fertile age group.
- **New clinical studies** indicating a higher incidence of fetal loss following vaccination in early pregnancy and a substantial decrease in live birth rates among vaccinated women.
- **Preclinical animal data** demonstrating potential biological mechanisms for harm, including irreversible damage to ovarian reserve and elevated inflammatory markers in reproductive tissues.
- **Rising reports of severe obstetric complications**, such as postpartum haemorrhage, in national quality databases.

These findings, detailed below in the appendix, represent clear safety signals that are not adequately addressed by regulators. While the burden of proof for safety lies with manufacturers and regulators, the duty of care for our patients lies with us.

As professionals in reproductive health, your observations are critical. We ask that you review the appended evidence and share with us your clinical experiences over the past five years. We wish to compile an evidence-based report of what is occurring in the area of reproductive health independent of any health agenda. We would like to know if you have observed changes in fertility outcomes, pregnancy complications, or neonatal health that you find concerning?

We seek an open, scientific dialogue to ensure the highest standards of patient safety and medical ethics. Your insights, even if shared anonymously, are invaluable.

The decisions we make now will shape the future of reproductive health for decades to come. We urge you to consider this information and join this critical conversation.

Please contact us at contactus@northgroup.info

With respect,

Representatives for NORTH Group,

Dr. Jeanne Rungby, MD
Dr. Jonathan Gilthorpe, PhD
Dr. Sven Román. MD
Dr. David Speicher, PhD

Dr. Ros Jones. MD
Hanna Parikka, MSc
Agita Galina. Mg.iur.



APPENDIX: Summary of Evidence

1. Lack of Pre-Approval Safety Data for Reproductive Health

- COVID-19 mRNA vaccines were recommended for pregnant women despite being excluded from initial clinical trials.
- Post-approval manufacturing changes introduced new components (e.g., synthetic plasmid DNA, SV40 promoter-enhancer) without additional Phase 3 trials.

2. Epidemiological Data: Declining Birth Rates

- A historic ~15% decline in birth rates began in Q1 2022 across most European countries following mass vaccination. This correlation demands further investigation into possible causation.

3. Key Recent Studies

- **Manniche *et al.* (2025):** A Czech nationwide cohort study found a 33% lower rate of live birth in vaccinated vs. unvaccinated women (18-45).
- **Guetzkow *et al.* (2025):** Analysis of 220,000 Israeli pregnancies found mRNA vaccination in weeks 8-13 was associated with higher-than-expected fetal loss, a signal not seen with influenza vaccines.
- **Thorp *et al.* (2025):** A VAERS analysis identified significant safety signals for 37 pregnancy-related adverse events, including miscarriage and neonatal complications.
- **Karaman *et al.* (2025):** A preclinical study in rats showed a >60% reduction in primordial follicles (the non-renewable egg supply) and a significant drop in AMH after administration of an mRNA vaccine, suggesting a potential mechanism for irreversible ovarian damage.

4. Clinical and Mechanistic Concerns

- **Postpartum Haemorrhage:** Danish mandatory reporting shows a marked increase in severe PPH (>1500ml) since 2021.
- **Immunological Mechanisms:** A 2024 study found a significant rise in anti-phospholipid antibodies post-vaccination, which are associated with recurrent miscarriage.
- **Nanoparticle Toxicity:** The LNPs used are a novel delivery system with unknown long-term biodistribution and effects on reproductive tissues.

References:

- [1] The Fertility Letter. NORTH Group, 2025. https://www.northgroup.info/api/pdfs/frt-letter/20250519_Fertility_letter_NORTH_Group.pdf
- [2] To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older, 2024. <https://clinicaltrials.gov/study/NCT04754594...>
- [3] European Births, Q2 2025 update, 2025. <https://cm27874.substack.com/p/european-births-q1-2025-update>
- [4] Rates of successful conceptions according to COVID-19 vaccination status: Data from the Czech Republic. Manniche V et al, 2025. <https://journals.sagepub.com/doi/10.1177/09246479251353384>
- [5] Observed-to-Expected Foetal Losses Following mRNA COVID-19 Vaccination in Early Pregnancy. Guetzkow J et al, 2025. <https://www.medrxiv.org/content/10.1101/2025.06.18.25329352v1>

- [6] Are COVID-19 Vaccines in Pregnancy as Safe and Effective as the Medical Industrial Complex Claim? Part I. Thorp J et al, 2025. <https://publichealthpolicyjournal.com/are-covid-19-vaccines-in-pregnancy-as-safe-and-effective-as-the-medical-industrial-complex-claim-part-i/>
- [7] Comparison of anti-phospholipid antibody titers before and after SARS-CoV-2 mRNA vaccination in hospital staff. Hisano M et al, 2024. <https://www.sciencedirect.com/science/article/pii/S2590136224001128>
- [8] Impact of mRNA and Inactivated COVID-19 Vaccines on Ovarian Reserve. Karaman E et al, 2025. <https://www.mdpi.com/2076-393X/13/4/345>
- [9] Danish Quality Database for Births, Annual Report 2024. https://www.sundk.dk/media/mwvjre05/dkf-aarsrapport-2024_offentlig.pdf
- [10] Danish Quality Database for Births, Annual Report 2023. <https://www.sundk.dk/media/mediefnz/e8d557a3cdf646f695e0b55cfccda6e4.pdf>
- [11] Ovarian toxicity of nanoparticles. Santacruz-Marques R et al, 2021. <https://www.sciencedirect.com/science/article/abs/pii/S0890623821000861?via%3Dihub>
- [12] Lay Summary, NORTH Group, 2024. https://northgroup.info/united-kingdom/pdf/NORTH_Group_Summary-2024-11-25_UK.pdf
- [13] COVID-19 Injections: Harms and Damages, a Non-Exhaustive Conclusion. Zywiec et al, 2025. <https://jpands.org/vol30no3/zywiec.pdf>
- [14] Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada. Speicher et al, 2025. <https://pubmed.ncbi.nlm.nih.gov/40913499/>